A prospective Study on prevalence and determinants of Ototoxicity dUring treatmeNt of childhooD cancer

Trial Data Center Princes Màxima Center for pediatric oncology0 个研究点目标入组 600 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•In order to be eligible to participate in stratum 1, a subject must meet all of the following criteria:
•1. Diagnosed with a CNS tumor or solid tumor in the Princess Máxima Center and
•2. Planned to receive treatment with cisplatin and/or carboplatin and/ or oxaliplatin and/or CNS-/ENT irradiation
•and/or CNS-/ENT surgery and
•3. Children aged 0 until 19 years at time of diagnosis.
•4. Biobank/ over de drempel PIF, Informed Consent Form (ICF) signed for collection of standard of care data.
•In order to be eligible to participate in stratum 2, a subject must meet all of the following criteria:
•1. Diagnosed with a CNS tumor or solid tumor in the Princess Máxima Center and
•2. Not planned to receive treatment with cisplatin and/or carboplatin and/or oxaliplatin and/or CNS-/ENT
•irradiation and/or CNS-/ENT surgery and
•3. Children aged 0 until 19 at time of diagnosis and
•4. Study specific informed consent form (ICF) signed prior to participation in the study.

•Critically ill, Intensive Care unit admission because of which audiological evaluation is not possible before
•start chemotherapy and/or CNS-/ENTradiotherapy and/or CNS-/ENT surgery

发起方

Trial Data Center Princes Màxima Center for pediatric oncology